EMERYVILLE, Calif., May 14, 2020 /PRNewswire/ -- Amyris, Inc. (Nasdaq:AMRS), a leading synthetic biotechnology company with leadership in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, announces that its first health and nutrition ingredient received a validation by a unanimous Panel of Medical Experts as Generally Recognized As Safe ("GRAS"). Following this successful validation, Amyris will submit an application for FDA GRAS approval of this ingredient (currently not being named due to partner's requirements), which has the highest level of purity available today at the lowest cost and is made from a sustainable production process using fermentation.
"We are very pleased with the medical Panel of Experts GRAS validation of our first health and nutrition ingredient. We are making very good progress with the development of ingredients in this category which are expected to develop into a comprehensive product line to advance our innovation leadership and support human health. The combination of our product offering and purity are unmatched in the industry and we believe this will lead to market success for this application of our technology," said John Melo, Amyris President and CEO.
Amyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 3,000 products from the world's top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands - all built around its No Compromise® promise of clean ingredients: Biossance™ clean beauty skincare, Pipette™ clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. For more information, please visit www.amyris.com.
This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as the expected submission of formal regulatory filings for a new health and nutrition ingredient and related approval and market entry for such ingredient, including costs thereof, anticipated new product line, and expected growth and leadership of Amyris's health and nutrition business. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo, No Compromise, Biossance, Pipette, and Purecane are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.
Note to Editors: Please see news release issued November 18, 2019 by Amyris entitled, "Amyris Advances to Regulatory Stage with Another Significant Health & Nutrition Molecule."
SOURCE Amyris, Inc.